Baird analyst Jeff Johnson raised the firm’s price target on Tandem Diabetes to $36 from $28 and keeps a Neutral rating on the shares. The firm said they posted 1Q revenue upside and a full-year guidance raise on early Mobi uptake. And with Mobi tailwinds likely growing as G7 integration happens 2Q, Baird believes the worst is likely behind them for now.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Wells upgrades Tandem Diabetes on positive endocrinologist survey
- Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo
- Leerink upgrades Tandem Diabetes to Outperform on attractive risk/reward setup
- Tandem Diabetes upgraded to Outperform from Market Perform at Leerink
- Tandem Diabetes price target raised to $40 from $37 at Stifel